Compromised chronic efficacy of a glucokinase activator AZD1656 in mouse models for common human GCKR variants.

Autor: Ford BE; Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK., Chachra SS; Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK., Alshawi A; Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK; Medical Laboratory Technique Department, Kufa Institute, Al-Furat Al-Awsat Technical University, Kufa, Iraq., Oakley F; Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK., Fairclough RJ; Emerging Innovations Unit, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Smith DM; Emerging Innovations Unit, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Tiniakos D; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK; Dept of Pathology, Aretaieion Hospital Medical School, National and Kapodistrian University of Athens, Greece., Agius L; Biosciences Institute, Newcastle University, Newcastle upon Tyne NE2 4HH, UK. Electronic address: Loranne.agius@ncl.ac.uk.

Publikováno v: Biochemical pharmacology [Biochem Pharmacol] 2024 Nov; Vol. 229, pp. 116499. Date of Electronic Publication: 2024 Aug 20.

The GCKR-P446L gene variant predisposes to raised blood cholesterol and lower blood glucose in the P446L mouse-a model for GCKR rs1260326.

Autor: Ford BE; Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK., Chachra SS; Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK., Rodgers K; Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK., Moonira T; Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK., Al-Oanzi ZH; Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK; Jouf University, Clinical Laboratory Science, Sakaka, Saudi Arabia., Anstee QM; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; Newcastle NIHR Biomedical Research Center, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK., Reeves HL; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; Newcastle NIHR Biomedical Research Center, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK., Schattenberg JM; Metabolic Liver Research Programm, Department of Medicine, University Hospital Mainz, Mainz, Germany., Fairclough RJ; Emerging Innovations Unit, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Smith DM; Emerging Innovations Unit, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Tiniakos D; Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK; Newcastle NIHR Biomedical Research Center, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK; Dept of Pathology, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece., Agius L; Biosciences Institute, Newcastle University, Newcastle upon Tyne, NE2 4HH, UK. Electronic address: loranne.agius@newcastle.ac.uk.

Publikováno v: Molecular metabolism [Mol Metab] 2023 Jun; Vol. 72, pp. 101722. Date of Electronic Publication: 2023 Apr 07.

Chronic glucokinase activator treatment activates liver Carbohydrate response element binding protein and improves hepatocyte ATP homeostasis during substrate challenge.

Autor: Ford BE; Biosciences Institute, Newcastle University, Medical School, Newcastle upon Tyne, UK., Chachra SS; Biosciences Institute, Newcastle University, Medical School, Newcastle upon Tyne, UK., Alshawi A; Biosciences Institute, Newcastle University, Medical School, Newcastle upon Tyne, UK., Brennan A; Newcastle Drug Discovery, Newcastle Centre for Cancer, School of Natural and Environmental Sciences, Newcastle University, Newcastle Upon Tyne, UK., Harnor S; Newcastle Drug Discovery, Newcastle Centre for Cancer, School of Natural and Environmental Sciences, Newcastle University, Newcastle Upon Tyne, UK., Cano C; Newcastle Drug Discovery, Newcastle Centre for Cancer, School of Natural and Environmental Sciences, Newcastle University, Newcastle Upon Tyne, UK., Baker DJ; Bioscience, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Smith DM; Emerging Innovations Unit, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Fairclough RJ; Emerging Innovations Unit, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Agius L; Biosciences Institute, Newcastle University, Medical School, Newcastle upon Tyne, UK.

Publikováno v: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2020 Nov; Vol. 22 (11), pp. 1985-1994. Date of Electronic Publication: 2020 Jul 07.

Metformin lowers glucose 6-phosphate in hepatocytes by activation of glycolysis downstream of glucose phosphorylation.

Autor: Moonira T; Biosciences Institute, Newcastle University, Medical School, Newcastle upon Tyne NE2 4HH, United Kingdom., Chachra SS; Biosciences Institute, Newcastle University, Medical School, Newcastle upon Tyne NE2 4HH, United Kingdom., Ford BE; Biosciences Institute, Newcastle University, Medical School, Newcastle upon Tyne NE2 4HH, United Kingdom., Marin S; Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Universitat de Barcelona, 08007 Barcelona, Spain; CIBEREHD and Metabolomics Node at INB-Bioinformatics Platform, Instituto de Salud Carlos III, 28029 Madrid, Spain., Alshawi A; Biosciences Institute, Newcastle University, Medical School, Newcastle upon Tyne NE2 4HH, United Kingdom., Adam-Primus NS; Biosciences Institute, Newcastle University, Medical School, Newcastle upon Tyne NE2 4HH, United Kingdom., Arden C; Biosciences Institute, Newcastle University, Medical School, Newcastle upon Tyne NE2 4HH, United Kingdom., Al-Oanzi ZH; Biosciences Institute, Newcastle University, Medical School, Newcastle upon Tyne NE2 4HH, United Kingdom., Foretz M; INSERM, U1016, Institut Cochin, Paris 75014, France; CNRS, UMR8104, Paris 75014, France; Université Paris Descartes, Sorbonne Paris Cité, Paris 75014, France., Viollet B; INSERM, U1016, Institut Cochin, Paris 75014, France; CNRS, UMR8104, Paris 75014, France; Université Paris Descartes, Sorbonne Paris Cité, Paris 75014, France., Cascante M; Department of Biochemistry and Molecular Biomedicine, Faculty of Biology, Universitat de Barcelona, 08007 Barcelona, Spain; CIBEREHD and Metabolomics Node at INB-Bioinformatics Platform, Instituto de Salud Carlos III, 28029 Madrid, Spain., Agius L; Biosciences Institute, Newcastle University, Medical School, Newcastle upon Tyne NE2 4HH, United Kingdom. Electronic address: loranne.agius@ncl.ac.uk.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2020 Mar 06; Vol. 295 (10), pp. 3330-3346. Date of Electronic Publication: 2020 Jan 23.